TCTR20220112006尚未招募1 期
An Open Label, Randomized, Two-Treatment, Two-Period, Single Oral Dose, Crossover Bioequivalence Study of TAGRELOR (90 mg) of the Government Pharmaceutical Organization, Thailand with BRILINTA (Ticagrelor 90 mg tablets) of AstraZeneca AB, Sweden in Healthy Human Subjects under Fasting Conditions
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •a)Normal, healthy, adult, both males and females subjects between 18 and 55 years of age (both inclusive).
- •b)Having a Body Mass Index (BMI) between 18.0 and 30.0 (both inclusive), calculated as weight in kg/height in m2.
- •c)Subject whose clinical laboratory values are within normal/acceptable reference ranges or clinically insignificant during screening as determined by physician or principal investigator to be of no clinical significance. If any subject has values outside of the pre-defined normal/acceptable range, the study physician/ Principal Investigator should have a clearly documented and medically rigorous justification for making that exception.
- •d)Normal medical history, clinical examination, 12 lead ECG, and chest X-ray recordings (postero-anterior view).
- •e)Able to understand and comply with the study procedures, in the opinion of the investigator.
- •f)Able to give voluntary written informed consent for participation in the trial.
- •g)In case of female subjects
- •- Surgically sterilized at least 06 months prior to study participation Or
- •- If of child bearing potential is willing to use a suitable and effective double barrier contraceptive method or intra uterine device during the study.And
- •- Urine pregnancy test must be negative.
排除标准
- •a)Known hypersensitivity to ticagrelor or any excipients or any related drug or any substance.
- •b)History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
- •c)Subjects who are being or have previously been treated for any GI problems or convulsive, depressive or hepatic disorders, and in whom there is a risk of a recurrence during the study period.
- •d)Ingestion or use of any medication (prescribed medication & over the counter (OTC) medication including herbal remedies and St. John Wort) at any time in 14 days prior to dosing of period-I. In any such case subject selection will be at the discretion of the Principal Investigator.
- •e)Any history of bronchospasm, asthma, urticaria or other allergic type reactions after taking any medication.
- •f) Consumption of grapefruits and grapefruit products within a period of 72 hours prior to dosing in Period-I.
- •g)Consumption of xanthine containing food or beverages (tea, coffee, chocolates or cola drinks) 24 hours prior to IMP administration of period-I.
- •h)Heavy smoking (More than 10 cigarettes/day).
- •i) Moderate smoking (More than 10 cigarettes/day) and consumption of tobacco containing products, which cannot stop smoking or consuming 24 hours prior to dosing and for entire duration of the study.
- •j) A recent history of harmful use of alcohol (less than 2 years), i.e. alcohol consumption of more than 14 standard drinks per week for men and more than 7 standard drinks per week for women (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40 percent distilled spirits, such as rum, whisky, brandy etc) or consumption of alcohol or alcoholic products within 48 hours prior to dosing in Period-I.
- •k)The presence of clinically significant abnormal laboratory values during screening.
- •l)Use of any recreational drugs or history of drug addiction or testing positive in pre study drug scans.
- •m)History or presence of seizure or psychiatric disorder.
- •n)A history of difficulty with donating blood.
- •o)Difficulty in swallowing solids dosage forms like tablets or capsules.
- •p)Donation of blood (1 unit or 350 mL) within a period of 90 days prior to the first dose of study medication.
- •q)Receipt of an investigational medicinal product or participation in a drug research study within a period of 90 days prior to the first dose of study medication
- •- If investigational medicinal product is received within 90 days where there is no blood loss except safety lab testing, subject can be included considering 10 half-lives duration of investigational medicinal product received.
- •r)History or presence of bleeding disorders or active bleeding from any site or any other clinically significant bleeding risk as judged by Principal Investigator/Clinical Investigator.
- •s)A positive hepatitis screen including hepatitis B surface antigen and/or HCV antibodies.
- •t)A positive test result for HIV antibody.
- •u)A positive test result for COVID-19 RT-PCR test through the nasopharyngeal swab.
- •v)An unusual diet, for whatever reason (for example, fasting, high potassium or low-sodium), for four weeks prior to receiving the study drug in period I. In any such case subject selection will be at the discretion of the Principal Investigator.
- •w)Nursing mothers (for female subjects).
研究者
相似试验
尚未招募
1 期
An Open Label, Randomized, Two-Treatment, Two-Period, Single Oral Dose, Crossover Bioequivalence Study of FAVIR of The Government Pharmaceutical Organization, Thailand with AVIGAN of FUJIFILM TOYAMA CHEMICAL CO., LTD., Japan, in Normal, Healthy, Adults Human Subjects under Fasting ConditionsHealthy male and female subjectsBioequivalenceFasting conditionsTCTR20210205002The Government Pharmaceutical Organization30
Unknown
1 期
An Open Label, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Oral Dose, Crossover BE Study of EXITIN (10 mg) of the Government Pharmaceutical Organization, Thailand with Lexapro of H.LUNDBECK A/S, Denmark in Normal, Healthy, Adult Human Subjects under Fasting ConditionsHealthy male and female subjectsBioequivalence fed conditionsTCTR20230208001The Government Pharmaceutical Organization28
尚未招募
1 期
An Open Label, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Oral Dose, Crossover BE Study of Rozacor (20 mg) of The Government Pharmaceutical Organization, Thailand with CRESTOR of IPR Pharmaceuticals Inc., Puerto Rico, in Healthy Human Subjects under Fasting ConditionsHealthy male and female subjectsBioequivalence fed conditionsTCTR20210521001The Government Pharmaceutical Organization50
尚未招募
1 期
An Open Label, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Oral Dose, Crossover BE Study of RALVIRINE (25 mg) of The Government Pharmaceutical Organization, Thailand with EDURANT (Rilpivirine 25 mg Tablets) of Janssen-Cilag S.p.A., Italy, in Healthy Subjects under Fed ConditionsHealthy male and female subjectsBioequivalence fed conditionsTCTR20210519006The Government Pharmaceutical Organization58
已完成
不适用
Bioequivalence study comparing Nevirapine Extended Release Tablet 400 mg of Apotex Inc. and Viramune® XR Extended-Release Tablet 400 mg of Boehringer Ingelheim Pty Limited., Australia in Patients Under Fasting Conditions in adult HIV-1 Infected patients stabilized on NevirapineCTRI/2015/06/005929Apotex Inc30